At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 162 enrolled
Drug / intervention
MM-121 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating MM-121 and Erlotinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 162 participants across 38 sites in 6 countries.
Detailed Summary
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesCanada, Germany, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2009
Enrollment StartFeb 2010
Primary CompletionNov 2014
Study CompletionJun 2015
TodayJul 2026
First PostedOct 14, 2009
Enrollment StartFeb 1, 2010
Primary CompletionNov 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.7 years ago
Interventions
MM-121drug
MM-121 (SAR256212) = intravenous solution
Erlotinibdrug
erlotinib = daily oral tablet